Advancing Psychedelic Clinical Study Design

The Reagan-Udall Foundation for the FDA, in collaboration with the FDA, hosted a virtual public workshop bringing together researchers, academics, industry, regulators, and other key stakeholders to discuss scientific issues that arise while working with psychedelics in clinical trials and drug development. This report summarizes the presentations and panel discussions from the workshop, exploring the scientific issues that arise while working with psychedelics in clinical trials and the evolving landscape of psychedelic research.